Switch to optionsXpress for advanced derivatives trading & earn 50 commission-free trades.
Advertisement
SureTrader Stock Hero Advertisement
Home > Boards > US OTC > Food - Processing and Agriculture >

Plandai Biotechnology, Inc. (PLPL)

PLPL RSS Feed
Add PLPL Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Aston Martin
Search This Board:
Last Post: 3/31/2015 5:17:00 AM - Followers: 182 - Board type: Free - Posts Today: 1


www.plandaibiotech.com

Movie by Plandai:
http://vimeo.com/95723836









Interview of CEO (Audio / February 14, 2012)
http://thestockradio.com/plpl-plandai-biotechnology-inc-v-p-global-director-of-marketing-sales-callum-baylis-duffield/

 
 

Security Details

 

Plandai Biotechnology, Inc. is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, "PLPL". As such, Business, operational and financial information on PLPL is fully transparent and available to public view.  

www.otcmarkets.com

  A/S :        500 million confirmed / State of Nevada
  O/S :                134.300.000 (Febr. 6th, 2015)
Free Float:           66.300.000 (Febr. 6th, 2015)

Incorporated in: NV,USA - Year of Inc.:  2012

                                                                                                                                                                                                                   Transfer Agent

Signature Stock Transfer, Inc., Transfer Agent, 2632 Coachlight Ct., Plano, TX, 75093, 972-612-4120

SignatureStock@aol.com


http://www.anneslie.org/times/News_icon.jpg

                                                                      Plandai Biotechnology, Inc.'s CEO Discusses Company's Plans for 2015____________________________________

NEW YORK, NY--(Marketwired - January 09, 2015) - Plandaí Biotechnology (PLPL) recently updated shareholders on a list of accomplishments reached in 2014, so Stock Market Media Group (SMMG), a research and content development investment relations firm, spoke with Plandaí's Chief Executive Officer, Roger Duffield, to discuss Plandaí's plans for 2015.

SMMG: First and foremost, can we get your reaction to the opening of your new production facility in South Africa and what does its completion mean for Plandaí in 2015?

Roger Duffield: "Well, opening the Senteeko facility is really the culmination of over a decade of research, sacrifice, and determination. Taking the initial concept that we could produce a highly bioavailable plant extract -- at a time when no one was even looking at the importance of bioavailability for nutraceuticals -- and then seeing it through to this point, has been an amazing journey that wouldn't have happened without the help and support of countless people. I get chills every time I visit Senteeko, drive thirty minutes on logging roads through thick forests, and then pass the gates to our estate and see the vast acres of tea with this amazing jewel of a factory sitting in the middle. I'm overwhelmed, excited, relieved, and deeply humbled all at the same time." 

SMMG: What is the significance of Plandaí's shift from a research and development company to a biotech that produces and sells products?

Roger Duffield: "Let me answer by first stating that Plandaí will always be a research and development company. When you look at the pharmacopeia of medicinal plants, you can see that there are hundreds of potential future research products for us. And even with just green tea catechins, we could spend a lifetime just on different human clinical trials as we explore the vast potential of this amazing plant.

"But, from a practical standpoint, now that the factory is opened, we can start generating revenues and positive cash flows. This will allow us to operate without dilution or incurring additional debt, expand our products lines, and return value to our shareholders. "Operationally, it means that we now have a whole new business model with new logistics. When you stop to think about what it takes to sell a product like Phytofare®, it requires so many moving parts working in harmony. Growing the leaf, picking it properly, manufacturing, batch testing, packaging, tracking and quality control, shipping, customs. Then you have the sales aspect, which includes marketing, trade shows, literature. It's really quite a process that I think few people fully understand."

SMMG: In 2013 Plandaí announced its entrance into the cannabis research arena, in 2014, the company secured a licensing agreement with Diego Pellicer and then obtained a consent letter from the Minister of Health in Uruguay to begin growing cannabis and producing an extract for animal testing, so what can we expect in 2015?

Roger Duffield: "Our plan at this point is to establish the cannabis growing infrastructure in Uruguay this year with an expectation of having an extract ready for testing six to nine months after it comes online. Our initial goal of having a product market-ready by the end of 2014 proved unrealistic once we determined that current U.S. laws, even in states where marijuana is legalized, prohibited us from legally acquiring cannabis, producing an extract, and then testing it inside the U.S. "Our operation in Uruguay will allow us to better control the chemical profile and then conduct our research into various neural disorders in a safe, legal, and scientifically validated manner. Also, we will be able to establish standards for dosage and chemical profile, which has so far been very limited with respect to cannabis research."

SMMG: After releasing the data in 2014 from a human clinical trial performed at North West University in South Africa that showed Plandaí's Phytofare® Catechin Complex demonstrated ten times greater bioavailability over a generic catechin extract, what is next in the on-going research at North West University?

Roger Duffield: "Starting this month, the research team at North West University in South Africa, under the supervision of the Dean's office of the Faculty of Health Sciences and the inventor of the Pheroid® delivery system, Prof. Anne Grobler, will complete the third arm of the bioavailability study. This final phase will use the same 26 human subjects, but this time the study will incorporate the addition of Pheroid® to the Phytofare® extract. "We anticipate that adding the Pheroid® delivery system will increase the overall bioavailability while also opening up the potential to use our extracts in less controlled applications such as adding Phytofare® to other ingredients including topical creams and liquids, and in environments where you are less able to control exposure to outside influences such as UV light, which kills the antioxidants."North West University will also be conducting our human weight loss clinical trial, which will test the Phytofare® versus a placebo over 90 days and involving 120 patients. This trial will also be looking at a complete blood panel so we can identify from a medical standpoint the effects of catechins on everything from blood sugar to cholesterol. The results could potentially open entirely new fields of research."

SMMG: Any closing thoughts?

Roger Duffield: "2015 promises to be a productive year for Plandaí. With the completion of the new laboratory inside the Senteeko facility, we plan to produce our first citrus extract and then test its bioavailability followed by a human clinical trial to confirm improved respiratory benefits including symptom relief for sinus, colds and the flu. And, as always, we continue to explore the medical potential of other phytonutrients and expect to test new extracts throughout the year."

__________________________________________________________________________________________________________________________________________________________________________________________________

For press releases please visit: www.plandaibiotech.com/press-release.html

_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________
 

                                                                                                                                                    PLANDAI BIOTECHNOLOGY at Africa                                                 

 

          


          

 

                                                                                                              Management Team
Roger Duffield President, Chief Executive officer and member of the Board of Directors

Callum Baylis-Duffield Vice-President and Global Director: Marketing Sales

David Rzepnicki Chief Financial Officer and member of the Board of Directors

Tim Matula Investor Relations and member of the Board of Directors

Contact:
Roger Duffield
Chief Executive Officer
Plandai Biotechnology, Inc.
1451 North 200 East, Suite 130C
Logan, UT 9810

(Validity unkown:
Corporate Headquarters Address: 2226 Eastlake Ave E, #156 Seattle, Washington, 98102, USA
Phone: (425) 466-0212
Website:              http://www.plandaibiotech.com
Email:                  Info@plandaibiotech.com

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PLPL
Current Price
Volume:
Bid Ask Day's Range
Wiki
PLPL News: Notice of Effectiveness (effect) 02/13/2015 06:01:43 AM
PLPL News: Securities Registration Statement (simplified Form) (s-3/a) 02/09/2015 05:18:41 PM
PLPL News: Securities Registration Statement (simplified Form) (s-3) 01/21/2015 04:28:14 PM
PLPL News: Quarterly Report (10-q) 11/14/2014 04:20:07 PM
PLPL News: Annual Report (10-k) 10/14/2014 09:59:18 AM
PostSubject
#12142   Just an FYI ,,,,,Interesting that it says, "The Getitgogone 03/31/15 05:17:00 AM
#12141   Woops lol here * brandao 03/24/15 08:40:44 PM
#12140   Hopeless hear unfortunately. brandao 03/24/15 08:39:30 PM
#12139   Something very strange: Those, who are running a Aston Martin 03/24/15 11:41:01 AM
#12137   As I said: Forget chart technique here. Worthless. Aston Martin 03/18/15 01:31:11 PM
#12136   well, simply said, just a pity to notice Aston Martin 03/18/15 01:30:08 PM
#12135   this wont ruin 1 bite of their big tmonkey 03/18/15 10:08:13 AM
#12134   March 2015 - and no sign of business Aston Martin 03/18/15 07:13:03 AM
#12132   Chart technique for highest risk pennystocks without income, Aston Martin 03/11/15 09:14:43 AM
#12131   $PLPL chart - closed above the middle Bollinger ospreyeye 03/11/15 02:34:31 AM
#12130   well, captainscotty, until now they are just easter Aston Martin 03/09/15 09:20:46 PM
#12129   Pity - but I must agree. Revenue counts Aston Martin 03/09/15 09:15:55 PM
#12128   Nice find, Ace! Thanks. tradetrak 03/09/15 09:03:19 PM
#12127   Always running around the fact that they still brandao 03/09/15 06:11:35 PM
#12126   News out today. ace1mc 03/09/15 09:24:40 AM
#12125   $PLPL One day we will be happy with captainscotty 03/08/15 05:55:31 AM
#12124   March 2015: Neither news about production, revenues nor Aston Martin 03/04/15 09:25:30 PM
#12123   Have been waiting since a while for those Aston Martin 02/25/15 12:44:32 PM
#12122   Tiny volumes meanwhile. No real news since months. Aston Martin 02/25/15 05:03:28 AM
#12121   Shively is the same crook as Duffield.. Duffield Aston Martin 02/16/15 11:02:37 AM
#12120   share price over next few months foreveralone 02/16/15 05:07:40 AM
#12119   One thing I can predict: Based on the Aston Martin 02/15/15 04:10:59 PM
#12118   We have received numberless of such news - Aston Martin 02/14/15 03:35:24 PM
#12117   $PLPL Good news ...Just keep adding on the bottom,,,:-} captainscotty 02/14/15 05:54:00 AM
#12116   I worry this story dies with tons of Aston Martin 02/13/15 08:58:44 AM
#12115   Lol yea man this needs another pump brandao 02/13/15 12:18:38 AM
#12114   shareprice of 2012 - 3 years for nothing! Aston Martin 02/12/15 11:14:08 AM
#12113   sorry, misunderstood. No news but this latest file Aston Martin 02/12/15 09:45:19 AM
#12112   What conclusion ? It was a question of brandao 02/12/15 09:32:26 AM
#12111   How do you come to this conclusion? Not Aston Martin 02/12/15 03:02:16 AM
#12110   Anything going on in plandai land brandao 02/11/15 02:36:52 PM
#12109   Definitive down trend: I doubt news will bring Aston Martin 01/29/15 12:49:04 PM
#12108   Do we see .15 again first half of 2015? Aston Martin 01/29/15 12:45:51 PM
#12106   No doubt, a totally useless person - Aston Martin 01/28/15 07:49:14 AM
#12105   What about ex microsoft executive? wallstreetbuyer 01/27/15 06:58:54 PM
#12104   Sorry, IMO never! My hopes for 'bucks' are Aston Martin 01/27/15 12:01:19 PM
#12103   Lol agreed Idc if it's real or fake brandao 01/27/15 10:46:07 AM
#12102   They can't be real because PLPL is just Aston Martin 01/27/15 07:34:25 AM
#12101   What page is that on ?..... This stock brandao 01/26/15 07:41:29 PM
#12100   I was looking at this company last year pridekillsjoyfills 01/22/15 04:02:17 PM
#12099   CEO Duffield - a big liar? Aston Martin 01/22/15 09:29:11 AM
#12098   In 2015: $0 revenues = $ 25.000.000 dilution? Aston Martin 01/22/15 06:47:47 AM
#12097   Does Duffield intent to fill his pockets heavily? Aston Martin 01/22/15 06:44:00 AM
#12096   Does PLPL dilute because revenues are not in Aston Martin 01/22/15 06:40:25 AM
#12095   News Jan 21st: 100.000.000 shares dilution ???????? Aston Martin 01/22/15 06:25:40 AM
#12094   Well, news releases of PLPL always sound very Aston Martin 01/21/15 10:49:27 AM
#12093   @Aston Martin, that's pretty impressive news for Plandai! jloerke 01/20/15 09:04:11 PM
#12092   NEWS: Plandai Biotechnology to Use "Trojan Horse" to Aston Martin 01/20/15 07:15:42 PM
#12091   Obvioulsy words of CEO Duffield do not count Aston Martin 01/16/15 12:21:49 PM
#12090   Yeah if they don't make any sales on brandao 01/15/15 12:18:14 PM
PostSubject